[1] |
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579(7798):265-269.
doi: 10.1038/s41586-020-2008-3
URL
|
[2] |
Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan:an analysis based on decade-long structural studies of SARS coronavirus[J]. J Virol, 2020, 94(7). DOI: 10.1128/jvi.00127-20.
doi: 10.1128/jvi.00127-20
|
[3] |
Maillard PV, Veen AG, Poirier EZ, et al. Slicing and dicing viruses:antiviral RNA interference in mammals[J]. EMBO J, 2019, 38(8):1.
|
[4] |
DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus(RSV)[J]. Antiviral Res, 2008, 77(3):225-231.
doi: 10.1016/j.antiviral.2007.11.009
URL
|
[5] |
Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses:strike and counterstrike[J]. Nat Biotechnol, 2007, 25(12):1435-1443.
doi: 10.1038/nbt1369
pmid: 18066040
|
[6] |
Wang Z, Ren L, Zhao X, et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells[J]. J Virol, 2004, 78(14):7523-7527.
pmid: 15220426
|
[7] |
Li T, Zhang Y, Fu L, et al. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication[J]. Gene Ther, 2005, 12(9):751-761.
pmid: 15772689
|
[8] |
Tang QQ, Li BJ, Woodle M, et al. Application of siRNA against SARS in the rhesus macaque model[M]// RNAi, 2008:139-158.
|
[9] |
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223):470-473.
doi: 10.1016/S0140-6736(20)30185-9
URL
|
[10] |
Chen Y, Liu Q, Guo D. Emerging coronaviruses:Genome structure, replication, and pathogenesis[J]. J Med Virol, 2020, 92(4):418-423.
doi: 10.1002/jmv.25681
pmid: 31967327
|
[11] |
Lundstrom K. Are viral vectors any good for RNAi antiviral therapy?[J]. Viruses, 2020, 12(10):1189.
doi: 10.3390/v12101189
URL
|
[12] |
Lundstrom K. Viral vectors applied for RNAi-based antiviral therapy[J]. Viruses, 2020, 12(9):924.
doi: 10.3390/v12090924
URL
|
[13] |
Srivastava A. Advances and challenges in the use of recombinant AAV vectors for human gene therapy[J]. Cell Gene Therapy Insights, 2016, 2(5):553-575.
doi: 10.18609/cgti
URL
|
[14] |
Mingozzi F, High KA. Immune responses to AAV vectors:overcoming barriers to successful gene therapy[J]. Blood, 2013, 122(1):23-36.
|
[15] |
Fitzpatrick Z, Leborgne C, Barbon E, et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction[J]. Mol Ther Methods Clin Dev, 2018, 9:119-129.
doi: 10.1016/j.omtm.2018.02.003
URL
|